Market research
MDWD Mediwound Ltd
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 172M
- P/E ratio
- Not available
- Analyst target
- 30.6667
- Dividend yield
- Not available
- Beta
- 0.09
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011316309
- Market cap
- 172M
- P/E ratio
- Not available
- Analyst target
- 30.6667
- Dividend yield
- Not available
- Beta
- 0.09
About
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Research context
Mediwound Ltd appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MDWD discussion.
5 years, 7 months ago
MediWound Ltd is currently in a long term downtrend where the price is trading 1.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
MediWound Ltd's total revenue rose by 22.6% to $7M since the same quarter in the previous year.
Its net income has increased by 49.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 43.3% to $-4M since the same quarter in the previous year.
Based on the above factors, MediWound Ltd gets an overall score of 3/5.